Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rowan E Miller

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Cancer Journal (Sudbury, Mass.)|December 14, 2021
Poly(ADP-Ribose) Polymerase Inhibitor Combination TherapyRowan E Miller
Expert Opinion on Investigational Drugs|August 1, 2013
The current state of pemetrexed in ovarian cancerRowan E Miller, Susana Banerjee
Therapeutic Advances in Medical Oncology|May 22, 2023
The role of PARP inhibitor combination therapy in ovarian cancerHelen Hockings, Rowan E Miller
Clinical Advances in Hematology & Oncology : H&O|August 4, 2016
The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparibRowan E Miller, Jonathan A Ledermann
Clinical Advances in Hematology & Oncology : H&O|September 28, 2016
The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutationsRowan E Miller, Jonathan A Ledermann
Histopathology|December 18, 2019
Targeted therapies in gynaecological cancersShanthini M Crusz, Rowan E Miller
Therapeutic Advances in Medical Oncology|January 16, 2023
Disparity in the era of personalized medicine for epithelial ovarian cancerMichael-John Devlin, Rowan E Miller
Current Opinion in Oncology|May 26, 2010
How to follow-up patients with epithelial ovarian cancerRowan E Miller, Gordon J S Rustin
The Oncologist|November 27, 2009
Combination systemic therapy for advanced renal cell carcinomaRowan E Miller, James M G Larkin
Future Oncology (London, England)|May 1, 2019
Olaparib maintenance for first-line treatment of ovarian cancer: will SOLO1 reset the standard of care?Rowan E Miller, Shanthini M Crusz, Jonathan A Ledermann
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Cancer Journal (Sudbury, Mass.)|December 14, 2021
Poly(ADP-Ribose) Polymerase Inhibitor Combination TherapyRowan E Miller
Expert Opinion on Investigational Drugs|August 1, 2013
The current state of pemetrexed in ovarian cancerRowan E Miller, Susana Banerjee
Therapeutic Advances in Medical Oncology|May 22, 2023
The role of PARP inhibitor combination therapy in ovarian cancerHelen Hockings, Rowan E Miller
Clinical Advances in Hematology & Oncology : H&O|August 4, 2016
The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparibRowan E Miller, Jonathan A Ledermann
Clinical Advances in Hematology & Oncology : H&O|September 28, 2016
The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutationsRowan E Miller, Jonathan A Ledermann
Histopathology|December 18, 2019
Targeted therapies in gynaecological cancersShanthini M Crusz, Rowan E Miller
Therapeutic Advances in Medical Oncology|January 16, 2023
Disparity in the era of personalized medicine for epithelial ovarian cancerMichael-John Devlin, Rowan E Miller
Current Opinion in Oncology|May 26, 2010
How to follow-up patients with epithelial ovarian cancerRowan E Miller, Gordon J S Rustin
The Oncologist|November 27, 2009
Combination systemic therapy for advanced renal cell carcinomaRowan E Miller, James M G Larkin
Future Oncology (London, England)|May 1, 2019
Olaparib maintenance for first-line treatment of ovarian cancer: will SOLO1 reset the standard of care?Rowan E Miller, Shanthini M Crusz, Jonathan A Ledermann
Pageof 4